Aspirin, Clonidine Don't Cut Post-Op Kidney Injury Risk
(HealthDay News) — For patients undergoing non-cardiac surgery, neither aspirin nor clonidine reduces the risk of acute kidney injury, according to a study published online Nov. 15 in the Journal of the American Medical Association. The research was published to coincide with the American Society of Nephrology's Kidney Week 2014, held from Nov. 11 to 16 in Philadelphia.
Amit X. Garg, M.D., Ph.D., from the London Health Sciences Centre and Western University in Canada, and colleagues conducted a randomized clinical trial involving 6,905 patients undergoing non-cardiac surgery from 88 centers in 22 countries. Patients were randomized to take aspirin or placebo before surgery and up to 30 days after surgery, and were assigned to take oral clonidine or placebo two to four hours before surgery and transdermal clonidine or placebo patch after surgery that remained for 72 hours.
The researchers observed no significant difference in the risk of acute kidney injury for aspirin versus placebo (13.4 versus 12.3 percent; adjusted relative risk, 1.10; 95 percent confidence interval, 0.96 to 1.25). There was also no significant difference noted in the risk for clonidine versus placebo (13.0 versus 12.7 percent; adjusted relative risk, 1.03; 95 percent confidence interval, 0.90 to 1.18). The risk of major bleeding was increased with aspirin, while clonidine correlated with increased risk of clinically important hypotension.
"Among patients undergoing major non-cardiac surgery, neither aspirin nor clonidine administered perioperatively reduced the risk of acute kidney injury," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.